Helicases as prospective targets for anti-cancer therapy.
Helicases as prospective targets for anti-cancer therapy.
复制标题
DOI：
10.2174/187152008784220339
复制
发表时间：
2008-05
影响因子：
2.8
通讯作者：
Rigu Gupta;R. Brosh
中科院分区：
文献类型：
--
作者：
Rigu Gupta;R. Brosh
已经提出，DNA修复途径的选择性失活可以增强通过DNA损伤剂或辐射的细胞毒性作用消除癌细胞的抗癌疗法。鉴于DNA解旋酶在DNA损伤反应、DNA修复和基因组稳定性维持中的独特且至关重要的作用，目前正在探索或用于对抗癌症的许多策略可以通过调节解旋酶功能来介导或增强。这篇综述的重点将是研究解旋酶在DNA修复中的作用，这些作用可能适合于癌症治疗方法。用抗癌药物如调节解旋酶表达或功能的小分子化合物治疗癌症是通过解旋酶依赖性DNA修复途径（特别是与DNA重组、复制重启和细胞周期检查点相关的那些）的失活来选择性杀死癌细胞的可行方法。
It has been proposed that selective inactivation of a DNA repair pathway may enhance anti-cancer therapies that eliminate cancerous cells through the cytotoxic effects of DNA damaging agents or radiation. Given the unique and critically important roles of DNA helicases in the DNA damage response, DNA repair, and maintenance of genomic stability, a number of strategies currently being explored or in use to combat cancer may be either mediated or enhanced through the modulation of helicase function. The focus of this review will be to examine the roles of helicases in DNA repair that might be suitably targeted by cancer therapeutic approaches. Treatment of cancers with anti-cancer drugs such as small molecule compounds that modulate helicase expression or function is a viable approach to selectively kill cancer cells through the inactivation of helicase-dependent DNA repair pathways, particularly those associated with DNA recombination, replication restart, and cell cycle checkpoint.